OnabotulinumtoxinA was shown to have a better outcome in patients with chronic migraine who have unilateral vs bilateral pain, fewer disability days per month, milder headache, and who started the treatment within 12 months of symptom onset, according to the results of a recent study published in the European Journal of Neurology.
A total of 725 patients with chronic migraine (85.5% women; mean age, 46.8 years) who failed to respond to ≥2 prophylactic agents were enrolled in this prospective study. The participants received onabotulinumtoxinA every 12 weeks over the course of one year. Information about headache intensity, quantity, and duration were recorded in a patient diary that was collected at 3 and 12 months.
After 1 year of treatment, the number of headaches per month was reduced by 50% in 79.3% of patients, and the mean number per month of migraines, analgesics taken, emergency room visits, and disability days, as well as headache intensity — assessed with the Visual Analog Scale — were all significantly reduced from baseline (P <.01 for all).
Compared with values at 3 months, the mean number per month of headaches and migraines, analgesics taken, and headache intensity were all significantly reduced at 12 months (P <.01 for all).
When onabotulinumtoxinA responders (n=575) were compared with nonresponders (n=150), the following factors were associated with response to onabotulinumtoxinA: unilateral pain (P =.02), fewer disability days per month at baseline (P =.001), lower headache intensity at baseline (P =.02), and initiation of treatment within 12 months of chronic migraine onset (P =.045). Most patients (94.9%) reported no adverse events at 12-month follow-up.
The researchers noted that, “starting treatment with onabotulinumtoxinA in the first year after [chronic migraine] diagnosis increases [the] chances of being a responder,” adding, “Our results regarding intensity of headache and days of disability per month support this ‘early-stage’ approach: chances of improvement are higher while pain is milder.”
They concluded that the results, “are especially interesting as time from diagnosis to treatment is one of the few factors that can be controlled by clinicians.”
Domínguez C, Pozo-Rosich P, Torres-Ferrús M, et al. OnabotuliumtoxinA in chronic migraine: predictors of response. A prospective multicentre descriptive study [published online November 24, 2017]. Eur J Neurol. doi: 10.1111/ene.13523
This article originally appeared on Clinical Pain Advisor